Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q1 2018 call → NOWe need to determine if the transcript describes a situation where the company is currently paying for something not yet earning, with a specific near-dated event that ends the wait, and management treats this as the main current work. Let's analyze. Key points from transcript: - The company has strong revenue growth, but there are mentions of investments and partnerships. - There is mention of "incremental R&D and commercial projects to capitalize on the momentum" and "planning some incremental R&D and commercial projects" - but that's future spending, not necessarily a current cost with a specific near-dated benefit. - There is mention of the iSeq platform: "we launched our iSeq platform in the first quarter and shipped units to customers for beta testing. During the beta test, we identified some opportunities to improve our corporate billing and shipping processes that will enhance product robustness and reliability. We are in the process of validating these improvements and expect to scale shipments midyear." This sounds like a product launch with a beta test, and they are paying for improvements, but is that a "waiting period" with a specific near-dated event? They expect to scale shipments midyear. That is a specific event. But is the company currently paying for something not yet earning? They have shipped beta units, but not yet scaled. However, the cost of beta testing and improvements is likely not a major financial burden relative to the company's size. Also, the company is not describing this as a major cost; it's just a product launch. - There is mention of "milestone payments associated with our recently announced oncology collaborations" - these are future revenue, not current costs. - There is mention of "Helix" - they invested $68 million in Helix, and they recognized a tax benefit. They also mention "Helix dilution" of about $0.06 per share in Q1, and expect $0.25 for the full year. So they are incurring losses from Helix. Is that a "waiting period" with a specific near-dated event? Helix is a consumer genomics company. The investment is ongoing, but is there a specific event that ends the wait? The transcript doesn't mention a specific near-dated event for Helix to become profitable. It's just an investment that is dilutive. That seems like an ongoing investment, not a defined waiting period with a specific crossing.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.